ALK and neoplasm: ALK+ NSCLC patients with tumour TP53 mutations at baseline (TP53mutbas) had a worse overall survival (OS) from the diagnosis of metastatic disease than patients with initially wild-type TP53 tumours (TP53wtbas, 44 vs. 62 months in median, p = 0.0182, Figure 1A).